Citas bibligráficas
Ugarte, S., (2023). Eficacia de la Efpeglenatida en el manejo de diabetes mellitus tipo 2 en adultos obesos: revisión sistemática y meta-análisis [Tesis, Universidad Privada Antenor Orrego]. https://hdl.handle.net/20.500.12759/10992
Ugarte, S., Eficacia de la Efpeglenatida en el manejo de diabetes mellitus tipo 2 en adultos obesos: revisión sistemática y meta-análisis [Tesis]. PE: Universidad Privada Antenor Orrego; 2023. https://hdl.handle.net/20.500.12759/10992
@misc{sunedu/3586421,
title = "Eficacia de la Efpeglenatida en el manejo de diabetes mellitus tipo 2 en adultos obesos: revisión sistemática y meta-análisis",
author = "Ugarte Carbajal, Sergio Robert",
publisher = "Universidad Privada Antenor Orrego",
year = "2023"
}
To evaluate the efficacy of efpeglenatide in the management of type 2 diabetes mellitus in obese adults through evidence synthesis in a systematic review and meta-analysis. Methods: Four medical databases were searched and included phase 2 or phase 3 randomized controlled trials evaluating obese adult patients with type 2 diabetes mellitus receiving efpeglenatide. Studies were evaluated using the RoB 2.0 method and summary of results (SoF) tables. Both the inverse variance approach and the random effects model were applied to the meta-analysis. Result: Six studies were included in the systematic review after full-text screening. A total of 3493 patients taking efpeglenatide and 1582 patients receiving placebo were enrolled. Efpeglenatide does not significantly reduce % HbA1c compared with placebo, both at doses of 4 to 8 mg (MD -0.32, CI95% -0.95 to 0.31) and at doses of 16 mg (MD -0.82, CI95% -1.18 to -0.46); Efpeglenatide reduces fasting plasma glucose (FPG) at doses of 4 to 8 mg (MD -7. 38, CI95% -23.38 to 8.52); at 16 mg doses, Efpeglenatide significantly reduces FPG compared to placebo (MD -16.20, CI95% -29.95 to -2.45); overall, Efpeglenatide decreases FPG compared to placebo (MD -11.63; CI95% -20.60 to -2.66; p= 0.01). When administered at a dose of 16 mg, efpeglenatide is associated with a higher risk of hypoglycemia than placebo (RR 4.45, CI95% 1.16 to 17.10). Efpeglenatide does not significantly reduce body weight in obese adults with diabetes mellitus at doses of 4 to 8 mg (MD -1.49, CI95 % -6.95 to 3.97), at doses of 16 mg (MD -5.75, CI95% -12.75 to 1.25), or overall (MD -3.10, CI95 % -7.41 to 1.20, p = 0.15).
Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons